Recursion Pharmaceuticals (RXRX) Non-Current Deferred Tax Liability (2022 - 2026)

Recursion Pharmaceuticals has reported Non-Current Deferred Tax Liability for 5 years, with the latest figure at $18.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 18.51% year-over-year to $18.3 million; the trailing twelve-month figure through Mar 2026 stood at $18.3 million (down 18.51% YoY), and the FY2025 full-year result was $23.3 million, down 74.63% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $18.3 million, down from $23.3 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $91.7 million in Q4 2024, with the low at $168000.0 in Q3 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $18.6 million across 5 years, with a median of $15.1 million in 2022.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability plunged 91.3% — and 2025, when it surged 13776.19%.
• Recursion Pharmaceuticals' Non-Current Deferred Tax Liability stood at $11.9 million in 2022, then sank by 88.78% to $1.3 million in 2023, then jumped by 6746.98% to $91.7 million in 2024, then sank by 74.63% to $23.3 million in 2025, then fell by 21.38% to $18.3 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $18.3 million (Q1 2026), $23.3 million (Q4 2025), and $23.3 million (Q3 2025), per Business Quant data.